Adcytherix
Last verified 2026-05-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $145.8Mattributed |
|---|---|
| Latest round | series-a, $113.4M, 2025-10-01attributed |
| Founded | 2024 |
| Headquarters | Marseille |
| Industry | bio |
| Stage | series-a |
| Website | adcytherix.com |
Adcytherix is a biopharmaceutical company developing novel antibody-drug conjugates for cancers with high unmet need. It targets cancer patients lacking effective options. Its pipeline is built around novel ADC payloads developed by a team carried over from Emergence Therapeutics.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-a | $113.4M | undisclosed |
Detected tech stack
Google Cloud CDN, Four, Sentry, core-js, WebsiteBuilder, Wix, Wix eCommerce, Google Cloud, React, lodash .
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $113.4M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $145.8M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | adcytherix.com, read 2026-05-16 |
| Description | self-reported | adcytherix.com, read 2026-05-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.